Stock News
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
Year: 2025
Stock News
Virtus Newfleet Multi-Sector Short Term Bond Fund Q2 2025 Commentary
Follow Summary The second quarter of 2025 was defined by several key policies from the new Trump administration, including tariffs/trade, immigration, and taxes. The fund returned 1.88% in the second quarter versus the ICE BoA […]
Forex News
Tesla (TSLA) Share Price Rises Ahead of Earnings Report
On 16 September, we noted signs of a strong market for Tesla (TSLA) shares, including:→ The price remaining above the psychological level of $400;→ Reaching the highest levels since late January. We also identified an […]